PortfoliosLab logoPortfoliosLab logo
CLOV vs. NKE
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

CLOV vs. NKE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Clover Health Investments, Corp. (CLOV) and NIKE, Inc. (NKE). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, CLOV achieves a 55.32% return, which is significantly higher than NKE's -30.16% return.


CLOV

1D
-2.14%
1M
37.74%
YTD
55.32%
6M
39.31%
1Y
17.74%
3Y*
60.44%
5Y*
-16.51%
10Y*

NKE

1D
0.18%
1M
2.58%
YTD
-30.16%
6M
-32.22%
1Y
-27.83%
3Y*
-24.37%
5Y*
-18.67%
10Y*
-0.61%
*Multi-year figures are annualized to reflect compound growth (CAGR)

CLOV vs. NKE - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
CLOV
Clover Health Investments, Corp.
55.32%-25.40%230.85%2.43%-75.01%-77.82%64.41%
NKE
NIKE, Inc.
-30.16%-13.83%-29.11%-6.01%-29.04%18.70%47.33%

Correlation

The correlation between CLOV and NKE is 0.25, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.25

Correlation (3Y)
Calculated over the trailing 3-year period

0.21

Correlation (5Y)
Calculated over the trailing 5-year period

0.30

Correlation (All Time)
Calculated using the full available price history since Jun 15, 2020

0.28

Fundamentals

Market Cap

CLOV:

$1.91B

NKE:

$64.86B

EPS

CLOV:

-$0.11

NKE:

$1.52

PS Ratio

CLOV:

0.85

NKE:

1.39

PB Ratio

CLOV:

5.62

NKE:

4.60

Total Revenue (TTM)

CLOV:

$2.21B

NKE:

$46.52B

Gross Profit (TTM)

CLOV:

$939.14M

NKE:

$18.99B

EBITDA (TTM)

CLOV:

-$55.21M

NKE:

$3.33B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CLOV vs. NKE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CLOV
CLOV Risk / Return Rank: 4949
Overall Rank
CLOV Sharpe Ratio Rank: 5050
Sharpe Ratio Rank
CLOV Sortino Ratio Rank: 5050
Sortino Ratio Rank
CLOV Omega Ratio Rank: 5050
Omega Ratio Rank
CLOV Calmar Ratio Rank: 4848
Calmar Ratio Rank
CLOV Martin Ratio Rank: 4848
Martin Ratio Rank

NKE
NKE Risk / Return Rank: 1313
Overall Rank
NKE Sharpe Ratio Rank: 1010
Sharpe Ratio Rank
NKE Sortino Ratio Rank: 1212
Sortino Ratio Rank
NKE Omega Ratio Rank: 1212
Omega Ratio Rank
NKE Calmar Ratio Rank: 1919
Calmar Ratio Rank
NKE Martin Ratio Rank: 1414
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CLOV vs. NKE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Clover Health Investments, Corp. (CLOV) and NIKE, Inc. (NKE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


CLOVNKEDifference
Sharpe ratioReturn per unit of total volatility

+0.99

Sortino ratioReturn per unit of downside risk

+1.80

Omega ratioGain probability vs. loss probability

1.11

0.88

+0.23

Calmar ratioReturn relative to maximum drawdown

0.32

-0.60

+0.93

Martin ratioReturn relative to average drawdown

0.58

-1.19

+1.78

CLOV vs. NKE - Sharpe Ratio Comparison

The current CLOV Sharpe Ratio is 0.26, which is higher than the NKE Sharpe Ratio of -0.73. The chart below compares the historical Sharpe Ratios of CLOV and NKE, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


CLOVNKEDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.26

-0.73

+0.99

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.19

-0.52

+0.34

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.02

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.19

0.41

-0.59

Drawdowns

CLOV vs. NKE - Drawdown Comparison

The maximum CLOV drawdown since its inception was -97.19%, which is greater than NKE's maximum drawdown of -75.19%. Use the drawdown chart below to compare losses from any high point for CLOV and NKE.


Loading charts...

Drawdown Indicators


CLOVNKEDifference

Max Drawdown

Largest peak-to-trough decline

-97.19%

-75.19%

-22.00%

Max Drawdown (1Y)

Largest decline over 1 year

-55.50%

-46.18%

-9.32%

Max Drawdown (3Y)

Largest decline over 3 years

-64.73%

-64.21%

-0.52%

Max Drawdown (5Y)

Largest decline over 5 years

-97.19%

-74.64%

-22.55%

Max Drawdown (10Y)

Largest decline over 10 years

-74.64%

Current Drawdown

Current decline from peak

-83.52%

-73.24%

-10.28%

Average Drawdown

Average peak-to-trough decline

-76.62%

-20.90%

-55.72%

Ulcer Index

Depth and duration of drawdowns from previous peaks

30.50%

23.33%

+7.17%

Volatility

CLOV vs. NKE - Volatility Comparison

Clover Health Investments, Corp. (CLOV) has a higher volatility of 22.48% compared to NIKE, Inc. (NKE) at 9.55%. This indicates that CLOV's price experiences larger fluctuations and is considered to be riskier than NKE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


CLOVNKEDifference

Volatility (1M)

Calculated over the trailing 1-month period

22.48%

9.55%

+12.93%

Volatility (6M)

Calculated over the trailing 6-month period

39.42%

29.22%

+10.20%

Volatility (1Y)

Calculated over the trailing 1-year period

68.65%

38.14%

+30.51%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

88.12%

35.81%

+52.31%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

85.63%

32.25%

+53.38%

Dividends

CLOV vs. NKE - Dividend Comparison

CLOV has not paid dividends to shareholders, while NKE's dividend yield for the trailing twelve months is around 3.72%.


PositionTTM20252024202320222021202020192018201720162015
CLOV
Clover Health Investments, Corp.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
NKE
NIKE, Inc.
3.72%2.53%2.00%1.28%1.07%0.68%0.71%0.89%1.11%1.18%1.30%0.93%

Financials

CLOV vs. NKE - Financials Comparison

This section allows you to compare key financial metrics between Clover Health Investments, Corp. and NIKE, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.002.00B4.00B6.00B8.00B10.00B12.00B14.00B20222023202420252026
749.19M
11.28B
(CLOV) Total Revenue
(NKE) Total Revenue
Values in USD except per share items

CLOV vs. NKE - Profitability Comparison

The chart below illustrates the profitability comparison between Clover Health Investments, Corp. and NIKE, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

-20.0%0.0%20.0%40.0%60.0%80.0%100.0%20222023202420252026
92.4%
40.2%
Portfolio components
CLOV - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Clover Health Investments, Corp. reported a gross profit of 692.13M and revenue of 749.19M. Therefore, the gross margin over that period was 92.4%.

NKE - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, NIKE, Inc. reported a gross profit of 4.53B and revenue of 11.28B. Therefore, the gross margin over that period was 40.2%.

CLOV - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Clover Health Investments, Corp. reported an operating income of 27.33M and revenue of 749.19M, resulting in an operating margin of 3.7%.

NKE - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, NIKE, Inc. reported an operating income of 553.00M and revenue of 11.28B, resulting in an operating margin of 4.9%.

CLOV - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Clover Health Investments, Corp. reported a net income of 27.33M and revenue of 749.19M, resulting in a net margin of 3.7%.

NKE - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, NIKE, Inc. reported a net income of 520.00M and revenue of 11.28B, resulting in a net margin of 4.6%.


Frequently Asked Questions


CLOV and NKE have a correlation of 0.25, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

CLOV has higher volatility (22.48%) compared to NKE (9.55%). In terms of maximum drawdown, CLOV dropped -97.19% vs NKE's -75.19%.

CLOV currently has the higher Sharpe Ratio (0.26 vs -0.73), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for CLOV and NKE

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer